HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kanebo Sensai Anti-Aging Skin Care Extends Into Foundations

This article was originally published in The Rose Sheet

Executive Summary

Sensai Cellular Performance foundations provide coverage in addition to "all the benefits of full-fledged skin care products," according to Kanebo

You may also be interested in...



Sales & Earnings In Brief

Colgate Q1: Colgate Luminous and Max Fresh helped drive U.S. toothpaste sales in the first quarter, firm says during April 26 earnings call. Colgate U.S. toothpaste market share rose 30 basis points to 36.5% year to date, company notes, citing ACNielsen data. North American sales grew 1.5% on a reported basis to $617.6 mil. and operating profit in the region declined 3% to $132.3 mil., primarily due to divestment of North American detergents business and increased ad spending, Colgate says. Net sales grew 4.5% on a reported basis to $2.87 bil. and net income was up 8% to $324.5 mil., including restructuring and stock compensation charges. Responding to an analyst question regarding the firm's interest in acquiring Pfizer's Listerine brand, CEO Reuben Mark said "it is in process, and I guess Pfizer or Pfizer's investment banking people will tell you that. There is an orderly process and...we're at stage X, [but] stage Y will be coming up." Pfizer recently announced it would consider selling its consumer unit, but noted it had no plans to divest individual brands (1"The Rose Sheet" Feb. 13, 2006, p. 7)...

Kao acquires Kanebo

Japanese company purchases Kanebo for approximately $2.37 bil. (¥1=$.0084) in stock, Kao announces Dec. 16. Company will acquire $2.24 bil. in stock from Japan's Industrial Revitalization Corporation Jan. 31 and $132.6 mil. in stock from Kanebo in mid-February, firm notes. Acquisition aims to "create one of the world's foremost cosmetics business groups," according to Kao. Kanebo will become a wholly owned subsidiary but will remain an "independent organization" with no changes to management, Kao adds. Firm was in talks to buy Kanebo in 2004, but bowed out of negotiations, after which the company was taken over by government-run IRCJ (1"The Rose Sheet" March 1, 2004, In Brief and 2"The Rose Sheet" May 17, 2004, In Brief). Kanebo generated net sales of $1.3 bil. in the nine months ended Sept. 30, and is expected to achieve sales of $1.7 bil. for the year ended Dec. 31, Kao says...

Mergers & Acquisitions In Brief

Kao buys Molton Brown: Japanese consumer products company acquired UK luxury personal care firm Molton Brown for $298 mil. (£1=$1.75) from Bridgepoint Capital, private equity firm announces July 15. Kao filed documents related to a potential acquisition of Molton Brown June 26 with Germany's Bundeskartellamt, or Federal Cartel Office, which enforces fairness laws in the country. Molton Brown markets color cosmetics, skin care, hair care and bath and body care, and is distributed in the U.S. in department and specialty store doors like Bloomingdale's, Neiman Marcus, Barneys New York and bluemercury, in addition to two standalone stores in New York City. Kao's beauty care portfolio includes mass market Jergens and Bioré skin care brands, Ban antiperspirants and John Frieda hair care, which the company acquired in 2002 (1"The Rose Sheet" Aug. 5, 2002, p. 5)...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014106

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel